TN-ARIES-CLEAN-TECH
19.11.2021 17:49:06 CET | Business Wire | Press release
Aries has reached another major milestone, achieving mechanical completion of the Aries Linden Biosolids Gasification Plant in Linden, New Jersey. This fluidized bed gasification plant is currently the largest facility of its type in the world. Commissioning is underway and is expected to be completed over the next few months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005608/en/
At full capacity, the plant will process 430 tons of biosolids daily (130,000 tons per year) diverting it from local landfills. This will also result in the production of approximately 22 tons per day of beneficial Bio-Fly-Ash™, a renewable product that will be sold as an additive to local concrete companies. The plant is located in a re-purposed building within the Linden Roselle Sewerage Authority (LRSA) complex.
“A special congratulations to Renus Kelfkens, Aries Executive Vice President - Engineering and all the Aries Clean Technologies team on this major milestone,” said Gregory Bafalis , CEO of Aries. “These teams have worked thousands of hours and delivered all fabrication and installation within two years from groundbreaking. I have no doubt this technology will become a new standard for the safe conversion of biosolids into beneficial use products.
“Currently 90% of the domestic Class A biosolids market is disposed of through ineffective conventional means such as landfilling, land application, or incineration. The fluidized bed technology can safely and efficiently stop this now and generate clean energy and Bio-Fly-Ash™,” Bafalis added.
“We’ve looked forward to celebrating this historic date that brings new technology and progress towards a cleaner environment to Linden and the Garden State,” said Derek Armstead , Mayor of Linden. “The Aries Build-Own-Operate model provides no financial risk to the LRSA or to the City of Linden but brings with it new, high-paying, green jobs in the clean tech industry for the people of Linden. And I’m so pleased that 16 new, permanent positions will bring this plant to life. We look forward to a long partnership with the Aries Linden team.”
Even before construction began, collaborations were underway with LRSA and the State of New Jersey Department of Environmental Protection (NJDEP). The awarding of the environmental permits not only validates Aries biosolids solutions but helps bring the state closer to its environmental goals. Permits addressed areas such as site use, soil conservation, air quality, water usage, and electrical generation and consumption.
Financing was provided in part through the sale of $61.5 million of “Green” tax-exempt bonds issued through the Union County Improvement Authority. Equity for the project comes principally from Aries Clean Technologies and Spring Lane Capital . “This project and Aries’ gasification technology fit perfectly with Spring Lane’s investment approach of partnering with leaders in the energy, water, food, and waste industries to help them deploy innovative, sustainable solutions. We are thrilled to support the Aries team on this and future projects,” said Nikhil Garg, General Partner at Spring Lane Capital.
Current research indicates that the fluidized bed gasification process will become an efficient method to address and destroy the quickly growing problem of per- and polyfluoroalkyl substances (PFAS). These man-made chemicals are used in many industrial applications and are very pervasive in the environment and human body. PFAS accumulates over time, leading to adverse health effects. Current studies show that the high temperature reached during the gasification process destroys any PFAS in biosolids as well as other bacteria, viruses, mold, fungus, etc.
The closed-loop system runs primarily on clean sustainable, renewable synthetic gas rather than relying on fossil fuels during operations. It is carbon negative and captures methane (with a global warming impact 23 times greater than CO2) that would otherwise be released into the atmosphere through the decomposition of biosolids. Greenhouse gases will also be reduced due to the reduction in trucking miles to reach existing, conventional disposal methods.
LRSA, created in 1948, services the City of Linden and the Borough of Roselle. It was established to contract and operate wastewater treatment and interceptor facilities to collect, treat, and dispose of sewage generated by the municipalities.
In addition to being the lowest cost option for biosolids disposal in the Linden area, the plant will serve the largest metropolitan area in the U.S., New York, that includes New York City, Long Island, and the Mid and Lower Hudson Valley in the state of New York and five of the largest cities in New Jersey: Newark, Jersey City, Paterson, Elizabeth, and Edison, and their vicinities.
About Aries Clean Technologies
Aries Clean Technologies, based in Franklin, Tennessee, develops, designs, and builds innovative proprietary fluidized bed and downdraft gasification systems and projects using its eight patents granted to date. Its projects provide for the sustainable conversion of biosolids and biomass, reduction of carbon emissions, and the production of clean thermal and electrical energy and beneficial Aries GREEN ® Biochar or Bio-Fly-Ash™. For more information, please visit our website: www.ariescleantech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005608/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom